Insider buying last 90 days
No open-market insider purchases were filed for INCY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every INCY insider filing, plotted on the chart in Gekko.Open INCY in Gekko
NASDAQ: INCY
Incyte (INCY) Stock Analysis & Forecast
Sep 28 close
$124.82+0.93 (+0.8%)
Gekko Brief
AI summaryIncyte this week centers on FDA approval of Atebrioz (zilurgisertib), developed with Mirum Pharmaceuticals, as the first oral ALK2 inhibitor for fibrodysplasia ossificans progressiva, a rare genetic ossification condition, which triggers a $25 million payment to Incyte. Following the approval, H.C. Wainwright raised its price target to $152 from $150 while maintaining a Buy rating, and JP Morgan raised its target to $123.00 from $120.00 while maintaining a Neutral rating, also noting a GF Score of 87/100 alongside a view that the stock is 17.1% overvalued.
Shares closed at $124.82, up 0.8%, sitting above both the 50-day average of $123.40 and the 200-day average of $106.40, with the 50-day above the 200-day. The GekkoIndex reads 57.7, placing the stock in the Neutral zone. Price sits 5.5% above Gekko Fair Value of $118.31. Trailing returns show a 1-month decline of 2.3% against a 6-month gain of 38.2% and a 1-year gain of 52.9%, with the 52-week range spanning $81.78 to $132.60.
Earnings are scheduled for 27 October 2026, before the open, 28 days out and inside a typical 20-trading-day holding window; the prior report on 28 July showed EPS of $2.80 against a $1.76 estimate, with a 6.9% reaction. Seasonality over the next 20 trading days has averaged a 1% return across 5 years, rising in 2 of them. No insider, Congress, or unusual options activity registers in the current windows. Analyst consensus across 21 firms shows 11 buy and 10 hold ratings, with a consensus target of $127.74.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Incyte price vs fair value
Close $124.82200-day averageGekko Fair Value $118.31
Incyte quick facts
- Market cap
- $25.30B
- P/E ratio
- 15.8
- Forward P/E
- 14.7
- EPS, TTM
- $7.85
- Revenue, TTM
- $5.82B
- Profit margin
- 27.7%
- Dividend yield
- —
- Beta
- 0.77
- Volume
- 1.43M avg 1.51M
- 1-year return
- +52.9%
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.4%
- 50-day average
- $123.40
- 200-day average
- $106.40
- Next earnings
- Oct 27 before open
- Shares outstanding
- 202.7M
Incyte swing-trade checklist
Incyte scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $124.82 is above the 50-day ($123.40) and 200-day ($106.40) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
57.7, Neutral
Reading 57.7 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
5.5% above
Price is 5.5% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Oct 27, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+1.0% on average
From this point in the calendar, the next 20 trading days averaged +1% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Incyte stock chart and price history
Incyte closed at $124.82 on Sep 28, 2026, +52.9% over the past year, inside a 52-week range of $81.78 to $132.60.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −2.3%
- 3 months
- +8.9%
- 6 months
- +38.2%
- 1 year
- +52.9%
The full INCY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open INCY in Gekko
Follow Incyte through every session
Put INCY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track INCY in GekkoFree for 7 days. No credit card required.
About Incyte
Incyte develops and sells medicines it discovers and researches itself, focusing on treatments for cancers and blood disorders. Its marketed products include Jakafi, used for myelofibrosis and polycythemia vera, Pemazyre, aimed at cancers driven by a specific enzyme abnormality, and Iclusig, prescribed for certain forms of leukemia. These approved therapies form the core of what the company is recognized for in the market today.
Beyond its current drugs, Incyte runs a pipeline of experimental treatments in various stages of clinical testing, covering conditions such as graft-versus-host disease, bladder cancer, lymphoma, endometrial cancer, and lung cancer, among others. The company works with a range of outside partners, including Novartis, Eli Lilly, and Agenus, and participates in joint clinical studies with firms such as MorphoSys and Xencor to test combination treatments for lymphoma patients. Its business relies on advancing both marketed drugs and this broader research pipeline through internal work and collaboration.
Incyte was founded in 1991 and is headquartered in Wilmington, Delaware. Its shares are listed on the NASDAQ under the ticker INCY.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- incyte.com
Incyte GekkoIndex: the smart money zone
Incyte’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.7, in the Neutral zone, up 0.3 points over five sessions.
57.7Neutral
Up 0.3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 39 | +0.2% | +2.8% | ||
| Accumulation | 164 | +1.2% | +1.0% | ||
| Neutral (current zone) | 409 | +0.6% | +3.8% | ||
| Distribution | 53 | 0.0% | 0.0% | ||
| Selling | 7 | Too few readings yet | |||
Average INCY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the INCY price, zone by zone.Track INCY in Gekko
Is Incyte stock overvalued? Gekko Fair Value
Incyte trades 5.5% above Gekko Fair Value of $118.31, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Incyte shares are worth, recalculated every trading day.
$118.31
Gekko Fair Value, Sep 29, 2026
5.5% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open INCY in Gekko
Incyte insider and Congress trading
No open-market insider purchases were filed for Incyte, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in INCY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for INCY, plotted on the chart in Gekko.Open INCY in Gekko
Buybacks
Incyte has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2026
- $6.89M
- As a share of market cap
- 0.03%
From company filings.
Incyte earnings: next date and track record
Incyte reports on Oct 27, 2026, before the open (28 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Oct 27, 2026
Expected before the open, 28 days away
- EPS estimate
- −$3.31
- Revenue estimate
- $1.47B
5 of 8reports beat the EPS estimate
±7.7%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 28, 2026 AI summary
- What they said
- Incyte reported Q2 2026 total revenue of $1.67 billion, up 38% YoY, with total net sales of $1.49 billion (+40% YoY), though excluding a one-time CMS settlement benefit, net sales grew 17%. Jakafi sales reached $817 million (+7% YoY) with 9% prescription demand growth. Key milestones include Jakafi XR launch ($10M Q2 sales), positive CHMP opinion for Opzelura, and acquisition of latarcibart (Phase III, von Willebrand disease) via the Vega transaction.
- Guidance
- Jakafi XR sales expected to reach $40-50 million in near term as formulary coverage targets 50-70% by year-end. Core business excluding Jakafi on track for $3-4 billion in net sales by 2030. Povorcitinib and Monjuvi regulatory approvals and launches anticipated through early 2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 28, 2026 | $2.80 est $1.76 | $1.67B est $1.50B | +6.9% |
| Apr 28, 2026 | $1.81 est $1.34 | $1.27B est $1.22B | +3.5% |
| Feb 10, 2026 | $1.80 est $1.90 | $1.51B est $1.35B | −9.3% |
| Oct 28, 2025 | $2.26 est $1.66 | $1.37B est $1.35B | −3.1% |
| Jul 29, 2025 | $1.57 est $1.39 | $1.22B est $1.26B | +10.5% |
| Apr 29, 2025 | $1.16 est $1.01 | $1.05B est $1.15B | +5.3% |
| Feb 10, 2025 | $1.43 est $1.55 | $1.18B est $1.00B | −10.5% |
| Oct 29, 2024 | $0.54 est $0.79 | $1.14B est $1.14B | +12.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Incyte stock forecast and analyst price targets
Analysts’ average 12-month price target for Incyte is $127.74, +2.3% from the last close, from 21 firms rating the stock in the last 90 days.
$127.74consensus 12-month target, +2.3% from the last close
Now $124.82Avg $127.74
Low $104High $155
Each firm’s latest rating in the last 90 days: 21 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | H.C. Wainwright | $152 | +21.8% |
| Sep 28 | J.P. Morgan | $123 | −1.5% |
| Sep 25 | H.C. Wainwright | $152 | +21.8% |
| Sep 25 | Bernstein | $104 | −16.7% |
| Sep 22 | RBC Capital | $109 | −12.7% |
+3.8%average 20-day move after past Neutral readings
+1.0%average move over the next 20 trading days in the last 5 years
±2.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Incyte seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Incyte averaged +1.0% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.2% | 3 of 5 |
| Next 10 trading days | −0.5% | 3 of 5 |
| Next 15 trading days | −0.4% | 3 of 5 |
| Next 20 trading days | +1.0% | 2 of 5 |
| Next 30 trading days | +11.2% | 3 of 5 |
For scale, INCY’s typical 20-trading-day move in either direction is about 5.4%.
Incyte market cap and key statistics
Incyte’s market cap is $25.30B, with a P/E ratio of 15.8 and revenue of $5.82B over the last twelve months.
Valuation
- Market cap
- $25.30B
- P/E ratio
- 15.8
- Forward P/E
- 14.7
- EPS, TTM
- $7.85
- Gekko Fair Value
- $118.31
Trading
- Volume
- 1.43M
- Avg volume, 20 days
- 1.51M
- 52-week high
- $132.60
- 52-week low
- $81.78
- Shares outstanding
- 202.7M
Financials
- Revenue, TTM
- $5.82B
- Profit margin
- 27.7%
- Return on equity
- 30.7%
- Quarterly earnings growth, YoY
- +37.7%
Risk and income
- Beta
- 0.77
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.4%
Incyte stock news this week
Coverage of Incyte this week reads positive: 9 positive, 4 neutral and 1 negative headlines.
- INCY Maintained by JP Morgan -- Price Target Raised to $123.00GuruFocus, Sep 28
- H.C. Wainwright raises Incyte stock price target on Atebrioz approval By Investing.comInvesting.com India, Sep 28
- Incyte takes FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressivaAllSci, Sep 28
- JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Ratingmarketscreener.com, Sep 28
- Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans ProgressivaBusiness Wire, Sep 25
- Form 4 Incyte Corporation For: 25 September By Investing.comInvesting.com Canada, Sep 25
Incyte peers
Incyte’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Incyte stock FAQ
What is Incyte’s market cap?
Incyte’s market cap is $25.30B at the Sep 28, 2026 close of $124.82, with 202.7M shares outstanding. The shares trade on a P/E ratio of 15.8.
What is the Incyte stock forecast?
The consensus analyst 12-month price target for Incyte is $127.74, +2.3% from the last close. Of the 21 firms that rated the stock in the last 90 days, 11 rate it a buy, 10 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Incyte stock overvalued or undervalued?
On Gekko’s estimate Incyte is overvalued: the Sep 28, 2026 close of $124.82 is 5.5% above Gekko Fair Value of $118.31. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Incyte report earnings next?
Incyte is expected to report on Oct 27, 2026, before the market opens (28 days away). Analysts expect earnings of −$3.31 per share on revenue of $1.47B. Incyte beat the earnings estimate in 5 of its last 8 reports, moving 7.7% on average across the report.
What is Incyte’s 52-week high and low?
Incyte’s 52-week high is $132.60 and its 52-week low is $81.78; it closed at $124.82 on Sep 28, 2026, +52.9% over the past year.
Is Incyte stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (trend), 2 as mixed (gekkoindex and seasonality) and 2 as headwinds (fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Incyte the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.